Ironwood Pharmaceuticals, Inc is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

RaQualia began operations in July 2008 with a corporate mission, "They seek to bring people health and happiness through innovative new medications." Thanks to the support of all of their stakeholders, the company was listed on the JASDAQ Growth Market in July 2011. They have transformed RaQualia's R&D strategy, which is now based on the concept of "selection and concentration." They are now focusing on their core competencies in targeting ion channels in the fields of pain and gastrointestinal disease. In addition, they have made a strategic decision to relocate RaQualia's discovery processes to Nagoya University to better promote synergy effects with academia. With the Chubu region as their base, they are continuing with further efforts enhance their capabilities in drug discovery, improve shareholder value, and achieve financial stability by promoting licensing activities and alliance management with their corporate partners. They will continue to work tirelessly in providing patients with innovative medicines sooner by increasing the pace of drug development. Thank you very much for your continued support of RaQualia.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

CardioSignal offers a digital cardiac biomarker for self-monitoring, remote care, and point-of-care diagnostics. CardioSignal's patented technology enables a digital cardiac biomarker for several major heart diseases, representing a breakthrough in the fight against heart disease, the world's most expensive and lethal disease. CardioSignal's digital cardiac biomarkers can replace invasive and expensive standard care technologies, allowing for faster and less expensive care.

Tropicana Products, Inc. manufactures and markets branded juice-based beverages. Its products include Tropicana Pure Premium, Tropicana Premium Drinks, Tropicana Essentials, Trop 50, and Tropicana Tropics. The company was founded by Anthony T. Rossi in 1947 and is headquartered in Purchase, NY.

Under the corporate philosophy of "Value Creation with Respect for Man's Life and Dignity", IL-YANG PHARM was established in 1946 and stepped forward with the growth of Korean pharmaceutical industry. Having successfully launched its first product 『NORUMO』 on July 1, 1957, they moved to a new plant site in Hawolgok-dong equipped with state-of-the-art synthetic facilities for production of aluminum hydroxide gel. Entering the 1960's, they quickly expanded under management modernization with new product development and sought multilateral changeover in management in the 19R70's. Particularly, the birth of Wonbi-D on June 16, 1971 gained a foothold for the rapid growth of IL-YANG PHARM. After founding Neusiline composition plant in Yongin in November 1972, they went through business opening in 1742 and became the 125th listed company in Korea.

AkPharma, Inc. is an American private company. The firm manufactures and markets dietary supplements.

Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, as well as other orphan indications.

Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.

Nippon Chemiphar Co., Ltd. engages in the healthcare business. It manufactures, sells, imports, and exports ethical pharmaceuticals and diagnostic agents. It operates through the Pharmaceuticals and Others segments. The Pharmaceuticals segment manufactures and sells prescription drugs. The Others segment includes safety testing consignment, healthcare, and real estate businesses. The company was founded by Akira Yamaguchi on June 16, 1950 and is headquartered in Tokyo, Japan.

New Pai Teng (Beijing) Pharmaceutical Technology Co., Ltd., established on 2018-05-21, Business scope includes technical promotion services;sell hygiene products;Sales of formula food for special medical purposes.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Sales of formula food for special medical purposes and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Shandong Inov New Material Co. Ltd. is a Chinese private company. The firm manufactures chemical products.

Otsuka Pharmaceutical Factory, Inc. manufactures and distributes pharmaceutical and nutritional products. Its products include medical foods, hine E-gel, processlead, engelead, innerpower, oronine h ointment, urepearl plus lotion 10 and urepearl plus cream. The company was founded on September 1, 1921 and is headquartered in Naruto, Japan.

POZEN, Inc. manufactures and markets pharmaceutical products. Its Pipeline products are PA Product Portfolio, which is focused on integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal damage. The firm PA Product Portfolio consists of PA8140 and PA32540. The company was founded by John R. Plachetka in 1996 and is headquartered in Raleigh, NC.

Luoyang Jiuheng Ship Special Materials Co., Ltd., established on 2004-06-30, Business scope includes insulation,sound insulation,sound absorption,Shock-absorbing special multi-functional fire-retardant products,Special Multifunctional Insulation Products,Chemical Products(Free of chemical hazards),Polymer Materials,Rubber products,Research and development of new building materials,Production,Sales.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH is a German private company located in Cologne. The firm manufactures pharmaceutical products. It was founded in 1826 by Maria Clementine. Hans-Helmut Fabry is currently the CEO of the company.